Natural cancer cure vaccine will is currently being tested. The first recipient of this vaccine is a woman from Britain.
Kelly Potter, 35, was diagnosed with advanced cervical cancer in July 2015 and was among the first to be enrolled on a cancer vaccine trial that will run over the next two years involving up to 30 volunteers.
At the same time, the patients on the trial will be prescribed a chemotherapy drug that should, at low doses, “lift the brakes” on the immune system so that it is no longer prevented from attacking the body’s own cancer cells, scientists said.
Ms Potter was injected with the vaccine on 9 February and has another seven visits to the hospital to complete the treatment. Doctors have warned her that she may experience flu-like symptoms, although none has appeared to far, she said.
“My hope for the future is to beat the cancer for as long as I can, and if I can’t, I have come to terms with that. I would like to go on and inspire others with cancer,” she said.
The vaccine contains a small fragment of protein from an enzyme called human telomerase reverse transcriptase (hTERT), which allows cancer cells to divide continuously. It is hoped that by injecting this antigen into the bloodstream, it will stimulate the immune system to make antibodies that attack cancer cells but leave normal, healthy cell untouched, scientists said.
“In this trial we are investigating a form of immunotherapy designed to activate the body’s immune system by administration of a vaccine based on fragments to a key cancer protein,” Professor Pandah said.
James Spicer, the chief investigator on the trial at Guy’s and St Thomas’ Biomedical Research Centre in London, said that low doses of a chemotherapy drug will be given to the patients alongside the vaccine in order to stimulate an effective immune response against tumour cells.
“The unique feature of this study is the use of additional agents to boost the vaccination response. It is hoped this will abolish the inhibitory effect of regulatory immune cells present in the patients’ circulation, which are believed to have limited the effectiveness of previous cancer vaccine approaches,” Dr Spicer said.